减肥药市场蓬勃发展，但各家分得的红利并不均等。

　　礼来公司股价周三盘前上涨超过8%。

　　此前，得益于减肥药Zepbound和Mounjaro的销售额飙升，该公司公布的季度销售额和利润均好于预期。

　　礼来公司预计，2026年全年销售额将较上年增长约25%，同样超出预期。

　　相比之下，诺和诺德股价在欧洲交易时段下跌18%，此前该公司周二警告称，由于其药物Wegovy和诺和泰（Ozempic）在美国面临定价压力，2026年的销售额降幅将比预期更大。

　　虽然诺和诺德是肥胖症药物市场的开拓者，但礼来公司已在多个方面超越了它，包括药物疗效、制造产能和直接面向消费者的销售策略。

　　今年，两家公司减肥药片的销售情况将成为关注焦点。诺和诺德已于今年早些时候推出了其药片，而礼来公司仍在等待美国食品药品管理局（FDA）的批准。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：李桐

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.